Note: Ingredients listed on restricted chemical lists
EC/CAS
202-966-0/101-68-8
Name of the chemical
4,4’-Methylenediphenyl diisocyanate
Concentration
>=0,1-<1 >=5% >=5% >=5% >=0,1%
General Information
Version
1.0
Revision date
2025-04-04
Product name
1C window adhesive Ultimate
1.2.1 Relevant identified uses
Adhesives Professional use product
Emergency telephone
+41 (0)61 705 91 11, +41 (0)61 705 97 97, +41 44 251 51 51
Icons in SDS
Company Information
company name
Würth AG
e-mail address of the competent person responsible for the Safety Data Sheet
prodsafe@wuerth.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H334
Hazard statements
Code
Statements
H334
May cause allergy or asthma symptoms or breathing difficulties if inhaled
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Classification
Signal word
Danger
Hazard statements
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Prevention
P261 Avoid breathing vapours. P284 Wear respiratory protection.
Response
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.
Disposal
P501 Dispose of contents/ container to an approved waste disposal plant.
Hazardous Ingredients
4,4'-Diphenylmethane diisocyanate
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. em- physema, bronchitis, reactive airways dysfunction syndrome).
